Format

Send to

Choose Destination
MAbs. 2013 Sep-Oct;5(5):655-9. doi: 10.4161/mabs.25439. Epub 2013 Jun 19.

Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis.

Author information

1
Department of Immunology; University of Texas Southwestern Medical Center; Dallas, TX USA.

Abstract

Much data support a role for central nervous system antigen-specific antibodies in the pathogenesis of multiple sclerosis (MS). The effects of inducing a decrease in (auto)antibody levels on MS or experimental autoimmune encephalomyelitis (EAE) through specific blockade of FcRn, however, remain unexplored. We recently developed engineered antibodies that lower endogenous IgG levels by competing for binding to FcRn. These Abdegs ("antibodies that enhance IgG degradation") can be used to directly assess the effect of decreased antibody levels in inflammatory diseases. In the current study, we show that Abdeg delivery ameliorates disease in an EAE model that is antibody dependent. Abdegs could therefore have promise as therapeutic agents for MS.

KEYWORDS:

EAE; FcRn; autoantibody; engineered antibodies; therapy

PMID:
23846320
PMCID:
PMC3851218
DOI:
10.4161/mabs.25439
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center